

Mhairi Copland

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6058870/mhairi-copland-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

2,032
citations

20
h-index

44
g-index

58
ext. papers

2,478
ext. citations

9.3
avg, IF

5.08
L-index

#	Paper	IF	Citations
51	Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. <i>Blood</i> , 2006 , 107, 4532-9	2.2	542
50	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. <i>Nature</i> , 2016 , 534, 341-6	50.4	141
49	EZH2 in normal and malignant hematopoiesis. <i>Leukemia</i> , 2014 , 28, 44-9	10.7	129
48	BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. <i>Blood</i> , 2008 , 111, 2843-53	2.2	108
47	Targeting hedgehog in hematologic malignancy. <i>Blood</i> , 2012 , 119, 2196-204	2.2	104
46	Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. <i>Blood</i> , 2013 , 122, 1293-304	2.2	98
45	Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. <i>Clinical Cancer Research</i> , 2006 , 12, 626-33	12.9	81
44	Developing collaborations to establish a low-cost advanced diagnostic hematology laboratory in Peshawar, Pakistan. <i>Blood Advances</i> , 2017 , 1, 36-38	7.8	78
43	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. <i>Lancet Haematology, the</i> , 2019 , 6, e375-e383	14.6	74
42	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. <i>Nature Reviews Cancer</i> , 2020 , 20, 158-173	31.3	74
41	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. <i>Lancet Haematology, the</i> , 2017 , 4, e310-e316	14.6	71
40	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. <i>Nature Medicine</i> , 2018 , 24, 450-462	50.5	69
39	Deregulated hedgehog pathway signaling is inhibited by the smoothed antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. <i>Scientific Reports</i> , 2016 , 6, 25476	4.9	54
38	Evolving molecular therapy for chronic myeloid leukaemia--are we on target?. <i>Hematology</i> , 2005 , 10, 349-59	2.2	34
37	How I manage priapism in chronic myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2012 , 158, 155-164	4.5	32
36	Hedgehog signaling in cancer stem cells: a focus on hematological cancers. <i>Stem Cells and Cloning: Advances and Applications</i> , 2015 , 8, 27-38	2.6	32
35	A telomere-associated secretory phenotype cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. <i>Leukemia</i> , 2014 , 28, 2028-39	10.7	27

34	A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. <i>Leukemia</i> , 2020 , 34, 1775-1786	10.7	26
33	Implementing the EffTox dose-finding design in the Matchpoint trial. <i>BMC Medical Research Methodology</i> , 2017 , 17, 112	4.7	22
32	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2020 , 34, 1613-1625	10.7	22
31	Chronic myelogenous leukemia stem cells: What's new?. <i>Current Hematologic Malignancy Reports</i> , 2009 , 4, 66-73	4.4	20
30	Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2474-8	1.9	19
29	Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. <i>Leukemia</i> , 2021 , 35, 1229-1242	10.7	18
28	Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323. <i>Blood</i> , 2014 , 124, 4539-4539	2.2	16
27	The role of the bone morphogenetic proteins in leukaemic stem cell persistence. <i>Biochemical Society Transactions</i> , 2014 , 42, 809-15	5.1	13
26	Is There a Role for Dose Modification of TKI Therapy in CML?. <i>Current Hematologic Malignancy Reports</i> , 2019 , 14, 337-345	4.4	12
25	BRD4-mediated repression of p53 is a target for combination therapy in AML. <i>Nature Communications</i> , 2021 , 12, 241	17.4	11
24	Targeting chronic myeloid leukemia stem cells. <i>Current Hematologic Malignancy Reports</i> , 2013 , 8, 14-21	4.4	10
23	The application of BH3 mimetics in myeloid leukemias. <i>Cell Death and Disease</i> , 2021 , 12, 222	9.8	9
22	Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. <i>Cell Death and Disease</i> , 2018 , 9, 927	9.8	9
21	Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. <i>Blood Advances</i> , 2016 , 1, 160-169	7.8	8
20	In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors. <i>Bone Marrow Transplantation</i> , 2014 , 49, 657-63	4.4	8
19	Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. <i>Expert Opinion on Drug Discovery</i> , 2017 , 12, 465-474	6.2	7
18	Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. <i>British Journal of Haematology</i> , 2018 , 182, 777-788	4.5	7
17	CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 49-49.2		7

16	Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. <i>Blood</i> , 2018 , 132, 457-457	2.2	6
15	Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. <i>Scientific Reports</i> , 2016 , 6, 24057	4.9	5
14	Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. <i>Cell Death Discovery</i> , 2021 , 7, 137	6.9	3
13	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.. <i>Lancet Haematology,the</i> , 2022 , 9, e276-e288	14.6	3
12	Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre experience. <i>Leukemia Research Reports</i> , 2013 , 2, 47-50	0.6	2
11	Dasatinib for the treatment of chronic phase chronic myeloid leukemia. <i>Clinical Practice (London, England)</i> , 2013 , 10, 415-425	3	2
10	Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia. <i>Future Oncology</i> , 2009 , 5, 455-8	3.6	2
9	Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.. <i>Lancet Haematology,the</i> , 2021 ,	14.6	2
8	ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy. <i>Science Translational Medicine</i> , 2021 , 13, eabd5016	17.5	2
7	Exploring Stem Cell Heterogeneity in Chronic Myeloid Leukemia. <i>Trends in Cancer</i> , 2018 , 4, 167-169	12.5	1
6	Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML). <i>Blood</i> , 2019 , 134, 3938-3938	2.2	1
5	Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 674-674	2.2	1
4	Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2016 , 128, 3057-3057	2.2	1
3	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.. <i>Lancet Haematology,the</i> , 2022 , 9, e262-e275	14.6	1
2	Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.. <i>Blood</i> , 2007 , 110, 2944-2944	2.2	
1	Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy. <i>Blood</i> , 2019 , 134, 2935-2935	2.2	2.3